4D Molecular Therapeutics’ (FDMT) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report published on Saturday,Weiss Ratings reports.

A number of other research analysts have also recently weighed in on the stock. Morgan Stanley dropped their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a report on Monday, January 13th. Leerink Partners cut their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Bank of America decreased their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.56.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $5.93 on Friday. The stock has a market capitalization of $274.14 million, a price-to-earnings ratio of -2.08 and a beta of 2.81. The business has a 50-day moving average of $5.97 and a 200 day moving average of $10.05. 4D Molecular Therapeutics has a 12 month low of $4.43 and a 12 month high of $36.25.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Large investors have recently bought and sold shares of the stock. Barclays PLC lifted its holdings in shares of 4D Molecular Therapeutics by 141.0% in the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after purchasing an additional 67,202 shares during the last quarter. Novo Holdings A S lifted its stake in 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after buying an additional 100,000 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $40,000. Braidwell LP grew its position in shares of 4D Molecular Therapeutics by 231.7% during the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after acquiring an additional 855,990 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of 4D Molecular Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company’s stock valued at $22,879,000 after acquiring an additional 37,232 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.